Adjuvant treatment of severe varicella pneumonia with intravenous varicella zoster virus-specific immunoglobulins

Research output: Contribution to journalArticle


Varicella zoster virus (VZV) pneumonia is associated with significant mortality, especially in the immunocompromised host. VZV-specific immunoglobulins (VZIG) are currently used as post-exposure prophylaxis for at-risk patients, but not as adjunctive therapy. A novel case of VZV pneumonia in an immunocompromised patient, treated successfully with intravenous VZIG in combination with acyclovir, is reported here.

Original languageEnglish
Pages (from-to)70-73
Number of pages4
JournalInternational Journal of Infectious Diseases
Publication statusPublished - Aug 1 2019



  • Immunocompromised host
  • Intensive care unit
  • Intravenous immunoglobulins
  • Pneumonia
  • Varicella zoster virus

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this